Highlighting 'Pay For Delay' Concerns
The U.S. Federal Trade Commission (FTC) has recently released two reports relating to the pharmaceutical industry. A significant theme in both reports is a concern that brand-name pharmaceutical companies are using...To view the full article, register now.
Already a subscriber? Click here to view full article